Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT6EN8
|
|||
| Drug Name |
PBCAR20A
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1/2 | [1] | ||
| Small lymphocytic lymphoma [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | ||
| Company |
Precision Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04030195) Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Precision Biosciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.